One week to go for the monthly UK regulators meeting. And TauRx on the other hand presented new data for HMTM in AD/PD conference - On 5 April 2025 at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, held in Vienna, Austria, during a symposium on “Tauopathies: challenges in targeting tau,” TauRx Therapeutics presented further analysis of data from its Phase III LUCIDITY (NCT03446001) trial, not previously presented, confirming the efficacy of LMTX (hydromethylthionine mesylate [HMTM]) for the treatment of mild cognitive impairment (MCI) and mild-to-moderate Alzheimer’s disease. LMTX is an oral small molecule that inhibits tau aggregation and has a secondary symptomatic effect of increasing levels of acetylcholine in the hippocampus. It is currently in pre-registration in the UK.

Most important are improving operations, if it willing to diversify the Miami, Bimini and Egypt operations could conservative cash out easily US1.5 billion which could substantially impose cash flow either reduce debt or standby casho bid for New York licence while focusing to expand revenue and profit contribution from natural gas and power operations. Combined and listing Las Vegas and New York if successful bidding and Alzheimer's drug if successful will be bonus.